Nykode Therapeutics (Vaccibody) småprat (NYKD)

[Jguiden]

Nevnte de skulle presentere noe nytt imorgen i Boston? Under en konferanse…

[safin]

Som vad ? Alltid något boston men inget konkret av detta sällskapet ….

[Boms]

Hvis du synes ledelsen er «håpløs» er det vel like greit å selge, for hvis du mener det du skriver er det jo faktisk ikke noe håp for selskapet

[safin]

Säljer ikke men tycker du ledelsen har gjort ett bra jobb?

[Roc]

Ser PDS Bio har rally i dag pga nye kliniske data fra HPV16 programmet.

Noen som vet om HPV programmet til PDS er overlappende eller i konkurranse med NYKD sitt HPV program eller?

DEVELOPING POWERFUL, SAFE, VERSATILE IMMUNOTHERAPIES

[Investor]

Q4 transcript utdrag

We are currently in Boston and looking forward to present new data from our antigen specific human tolerance efforts at this highly relevant conference, Antigen Specific Immune Tolerance Summit, going on this week. And we will present a lot of interesting data tomorrow.

https://www.investing.com/news/transcripts/earnings-call-transcript-nykode-therapeutics-q4-2024-revenue-jumps-stock-up-93CH-3892614

Kommer vel en melding da kanskje.

Videre,

So as you may all be aware of, there has been limited transactions in the field of cancer vaccines since Michael was very active in the space in 2020 and 2021. We now see that that is changing in the landscape, being very aware of what’s happening in the field of cancer vaccines in early stage. So that’s positive for Nykode and also regaining the rights from VB10.NEO.

Om tolerance,

While in the field of immunotolerance and also specifically in the field of antigen specific immune tolerance, we see a very active space with multiple pharma companies saying that’s really false within their strategy and we see also transactions on a preclinical stage. And if you look at our data and we’ll also see multiple data tomorrow, what we have here with our platform is really differentiating from the other technologies being explored in the field. And we are getting closer and closer to be in a position to continue to support the differentiation and the ability we have when we are changing our Hc targeting units and modulating in response to different directions. So we are focusing really here on the preclinical path to be able to support those partnership discussions that we are currently seeing. So what really differentiates our platform compared to others.

[Boms]

Blir spennende å se hva som kommer i morgen!

[safin]

Vilken tid är de imorgon i boston ?

[Boms]

Pussig hva man finner om man bruker den nye søkemotoren som kaller seg Google :

= 18:30 norsk tid.

[safin]

Kommer de börsmelding tror vi?

[Peterdawn]

Hvorfor er det så vanskelig å få til et samarbeid når dataene er så gode? Det er umulig for meg å forstå.

[TekBot]

Nykode Therapeutics Announces Preclinical Data Highlighting its Immune Tolerance Platform’s Ability to Modulate Multiple Key Immune Components in Autoimmune Disease

• New preclinical data indicates effect on all major components of immune system involved in autoimmune diseases
• Data presented at the 8th Antigen-Specific Immune Tolerance Drug Development Summit (ASIT) in Boston

…

Vis børsmeldingen

Oslo, Norway, February 27, 2025 – Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new preclinical findings reinforcing the unique mechanism of action and potential of its APC-targeted immune therapy platform in treating autoimmune diseases.

Important new data show that Nykode’s APC-targeted constructs increase antigen-specific regulatory T cells, which are known to downregulate an unwanted immune response, while simultaneously reducing antigen-specific effector T cells that drive inflammation. Furthermore, new data show that Nykode’s APC-targeted constructs can reduce the generation of antigen-specific IgG autoantibodies, thereby shaping also the humoral component of the immune response, which is known to be involved in many autoimmune conditions. These changes suggest that the therapy works effectively through multiple arms of the antigen-specific immune system to promote its effectiveness and support its potential as a future therapy for autoimmune disorders, allergy and organ transplant rejection.

Furthermore, new data show that Nykode’s APC-targeting unit is essential for the observed increased effect in alleviating disease symptoms across preclinical autoimmune models, demonstrating the versatility and efficacy of the platform.

“These novel data deepen our confidence in the underlying mechanisms of our APC-targeted therapy platform and its potential in treating conditions caused by an unwanted immune response, such as autoimmune diseases,” said Agnete Fredriksen, Chief Scientific Officer and Co-founder of Nykode. “We are encouraged by the ability to measure the effect through multiple arms of the immune system, which reinforces our opportunity to build on the strength and diversity of our unique APC-technology to drive highly specific and customized immune tolerance.”

Most of the data have been generated using MOG and PLP-1 antigens, which are applicable in chronic and relapsing-remitting EAE models.

Nykode remains committed to advancing its immune tolerance platform and further exploring the clinical potential of APC-targeted therapy for autoimmune diseases, allergies, and organ transplant rejection.

The poster and presentation are available on the Nykode website at https://nykode.com/research-and-development/scientific-papers-and-presentations.

About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular immunotherapy technology specifically targets antigens to antigen presenting cells (APC), which have been shown to induce a broad, strong and long-lasting antigen specific immune response in cancer, which correlates with clinical responses.

Nykode’s lead product candidates are VB10.16, a therapeutic immunotherapy for the treatment of HPV16 induced malignancies which demonstrated favorable safety and efficacy results from its Phase 2 trial for the treatment of cervical cancer. VB10.NEO, an individualized cancer neoantigen immunotherapy, is being investigated in a trial with more than 10 different indications.

The Company’s partnerships include a multi-target collaboration with Regeneron in oncology and infectious diseases.

Nykode is also utilizing its APC-targeted technology to create an immune tolerance platform for the potential use in autoimmune disorders, organ transplant rejections, anti-drug antibody reactions and allergy.

Nykode Therapeutics’ shares are traded on the Oslo Stock Exchange (OSE: NYKD). Further information about Nykode Therapeutics can be found at http://www.nykode.com.

Forward-looking statements for Nykode Therapeutics
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect the company’s current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.

Contact for Nykode Therapeutics ASA:
Alexandra Deschner, Head of IR
Nykode Therapeutics ASA
IR@nykode.com

Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway

Kilde

[Boms]

Der kom dagens fra Nykode på websiden:

2025-ASIT_poster_Nykode_final_pdf.pdf

[safin]

Dom som kan detta , hur tolkar ni de?

[polygon]

@Roc

Er ikke dette de samme dataene som er vist tidligere?

Spørsmålet er hvordan man kan diagnostisere MS pasienter før de får manifest MS for så å vaksinere dem?

Dette er et profylaktisk design og ikke relevant for klinikken. På samme måte som flere (hvis ikke alle) cancer modellene de har vist også har, først vaksine og deretter induksjon av cancer.

De har hørt på deg @Roc (og for så vidt meg også: Nykode Therapeutics (Vaccibody) småprat (NYKD) - #3158 av polygon)

Fra dagens presentasjon og (den nye) MS-modellen:

[Peterdawn]

Jeg synes jo dette ser veldig spennende ut. Tar sikkert litt tid før markedet bryr seg gitt historikken.

[Investor]

Shortangrep eller info på avveie i NYKD?

[Matadoren]

Har tatt i mot kniven ett par ganger allerede, skremmende at det ikke finnes kjøpere, satser på at short avdelingene har fått nye rammer for mars måned.

[Andor]

Sikkert dette som er grunnen.

https://e24.no/boers-og-finans/i/93L3r5/kreftdoeden-paa-oslo-b

[Roc]

Tror RFK jr kke er så pro mRNA/DNA vaksiner…han er nok heller negativ til denne type vaksiner/genterapi